Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma

NCT05168423 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT05168423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05168423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 24, 2023
Completion date
December 19, 2039
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma